These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15581898)

  • 21. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
    Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
    Mehle A; Goncalves J; Santa-Marta M; McPike M; Gabuzda D
    Genes Dev; 2004 Dec; 18(23):2861-6. PubMed ID: 15574592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
    Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
    Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
    Alce TM; Popik W
    J Biol Chem; 2004 Aug; 279(33):34083-6. PubMed ID: 15215254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
    Khan MA; Kao S; Miyagi E; Takeuchi H; Goila-Gaur R; Opi S; Gipson CL; Parslow TG; Ly H; Strebel K
    J Virol; 2005 May; 79(9):5870-4. PubMed ID: 15827203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protecting APOBEC3G: a potential new target for HIV drug discovery.
    Stopak K; Greene WC
    Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions.
    Khan MA; Goila-Gaur R; Opi S; Miyagi E; Takeuchi H; Kao S; Strebel K
    Retrovirology; 2007 Jul; 4():48. PubMed ID: 17631688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G.
    Sugiyama R; Nishitsuji H; Furukawa A; Katahira M; Habu Y; Takeuchi H; Ryo A; Takaku H
    J Biol Chem; 2011 Mar; 286(12):10051-7. PubMed ID: 21228271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Suspène R; Sommer P; Henry M; Ferris S; Guétard D; Pochet S; Chester A; Navaratnam N; Wain-Hobson S; Vartanian JP
    Nucleic Acids Res; 2004; 32(8):2421-9. PubMed ID: 15121899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
    Goncalves J; Santa-Marta M
    Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
    Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
    Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
    Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?
    Carr JM; Davis AJ; Feng F; Burrell CJ; Li P
    Curr Drug Targets; 2006 Dec; 7(12):1583-93. PubMed ID: 17168833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
    Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    Kaiser SM; Emerman M
    J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.